Stay updated with breaking news from Adicet Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative...
As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual MeetingCompany to host ADI-001 webcast event on December 11, 2022 at 9:00 a.m. ETOn track to initiate a potentially pivotal program f...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on October 31,... | October 31, 2022
BioAR Trial is a new accelerator that will provide companies a guaranteed clinical trial site at one of the hospitals and health systems partnered with the program. Applications are being accepted for the first cohort of companies, which will begin in April.